{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:32:38Z","timestamp":1792427558579,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11910-025-01415-9","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T15:38:27Z","timestamp":1743349107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management"],"prefix":"10.1007","volume":"25","author":[{"given":"Barun Kumar","family":"Sen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambar","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1415_CR1","first-page":"198","volume":"32","author":"RD Adams","year":"1953","unstructured":"Adams RD, Foley JM. The neurological disorder associated with liver disease. Res Publ Assoc Res Nerv Ment Dis. 1953;32:198\u2013237.","journal-title":"Res Publ Assoc Res Nerv Ment Dis"},{"key":"1415_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/bmj.282.6260.263","volume":"282","author":"JB Saunders","year":"1981","unstructured":"Saunders JB, Walters JR, Davies AP, Paton A. A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed). 1981;282:263\u20136.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"1415_CR3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.23500","volume":"51","author":"P Jepsen","year":"2010","unstructured":"Jepsen P, Ott P, Andersen PK, S\u00f8rensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51:1675\u201382.","journal-title":"Hepatology"},{"key":"1415_CR4","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/BF01320309","volume":"31","author":"G D\u2019amico","year":"1986","unstructured":"D\u2019amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31:468\u201375.","journal-title":"Dig Dis Sci"},{"key":"1415_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.510280508","volume":"28","author":"W Nolte","year":"1998","unstructured":"Nolte W, Wiltfang J, Schindler C, M\u00fcnke H, Unterberg K, Zumhasch U, et al. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998;28:1215\u201325.","journal-title":"Hepatology"},{"key":"1415_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s11547-017-0770-6","volume":"122","author":"P Fonio","year":"2017","unstructured":"Fonio P, Discalzi A, Calandri M, Doriguzzi Breatta A, Bergamasco L, Martini S, et al. Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and Temporal grading classification. Radiol Med. 2017;122:713\u201321.","journal-title":"Radiol Med"},{"key":"1415_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11011-011-9242-1","volume":"26","author":"MM Lauridsen","year":"2011","unstructured":"Lauridsen MM, Jepsen P, Vilstrup H. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease. Metab Brain Dis. 2011;26:135\u20139.","journal-title":"Metab Brain Dis"},{"key":"1415_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/hep.21586","volume":"45","author":"M Romero-G\u00f3mez","year":"2007","unstructured":"Romero-G\u00f3mez M, C\u00f3rdoba J, Jover R, del Olmo JA, Ram\u00edrez M, Rey R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology. 2007;45:879\u201385.","journal-title":"Hepatology"},{"key":"1415_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ajg.2015.377","volume":"111","author":"S Allampati","year":"2016","unstructured":"Allampati S, Duarte-Rojo A, Thacker LR, Patidar KR, White MB, Klair JS, et al. Diagnosis of minimal hepatic encephalopathy using Stroop encephalapp: a multicenter US-based, norm-based study. Am J Gastroenterol. 2016;111:78\u201386.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1415_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jhep.2015.07.007","volume":"63","author":"P Jepsen","year":"2015","unstructured":"Jepsen P, Watson H, Andersen PK, et al. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. J Hepatol. 2015;63(5):1133\u20138.","journal-title":"J Hepatol"},{"issue":"12","key":"1415_CR11","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/gutjnl-2020-321631","volume":"69","author":"JMD Nightingale","year":"2020","unstructured":"Nightingale JMD, Paine P, McLaughlin J, et al. The management of adult patients with severe chronic small intestinal dysmotility. Gut. 2020;69(12):2074\u201392.","journal-title":"Gut"},{"issue":"6","key":"1415_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s11011-015-9743-4","volume":"31","author":"VC Patel","year":"2016","unstructured":"Patel VC, White H, Stoy S, et al. Clinical science workshop: targeting the gut-liverbrain axis. Metab Brain Dis. 2016;31(6):1327\u201337.","journal-title":"Metab Brain Dis"},{"issue":"Suppl 1","key":"1415_CR13","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jhep.2020.11.013","volume":"75","author":"J Trebicka","year":"2021","unstructured":"Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021;75(Suppl 1):S67\u201381.","journal-title":"J Hepatol"},{"issue":"5","key":"1415_CR14","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.mayocp.2015.03.003","volume":"90","author":"EB Tapper","year":"2015","unstructured":"Tapper EB, Jiang ZG, Patwardhan VR. Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy. Mayo Clin Proc. 2015;90(5):646\u201358.","journal-title":"Mayo Clin Proc"},{"key":"1415_CR15","doi-asserted-by":"crossref","unstructured":"Cheon SY, Song J. The association between hepatic encephalopathy and diabetic encephalopathy: the brain-liver axis. Int J Mol Sci 2021;22(1).","DOI":"10.3390\/ijms22010463"},{"issue":"12","key":"1415_CR16","doi-asserted-by":"publisher","first-page":"e0261377","DOI":"10.1371\/journal.pone.0261377","volume":"16","author":"OM Agbalajobi","year":"2021","unstructured":"Agbalajobi OM, Gmelin T, Moon AM, et al. Characteristics of opioid prescribing to outpatients with chronic liver diseases: a call for action. PLoS ONE. 2021;16(12):e0261377.","journal-title":"PLoS ONE"},{"issue":"6","key":"1415_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/apt.15639","volume":"51","author":"AM Moon","year":"2020","unstructured":"Moon AM, Jiang Y, Rogal SS, et al. Opioid prescriptions are associated with hepatic encephalopathy in a National cohort of patients with compensated cirrhosis. Aliment Pharmacol Ther. 2020;51(6):652\u201360.","journal-title":"Aliment Pharmacol Ther"},{"key":"1415_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60:715\u201335.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"1415_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40265-018-1018-z","volume":"79","author":"K Weissenborn","year":"2019","unstructured":"Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs. 2019;79(Suppl 1):5\u20139. -1018-z.","journal-title":"Drugs"},{"issue":"5","key":"1415_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.7861\/clinmedicine.9-5-466","volume":"9","author":"JM Pearce","year":"2009","unstructured":"Pearce JM. Hugo Karl Liepmann and apraxia. Clin Med (Lond). 2009;9(5):466\u201370.","journal-title":"Clin Med (Lond)"},{"key":"1415_CR21","doi-asserted-by":"crossref","unstructured":"Davidson EA, Summerskill WH. Psychiatric aspects of liver disease. Postgrad Med J. 1956; OCT:48.","DOI":"10.1136\/pgmj.32.372.487"},{"issue":"6836","key":"1415_CR22","first-page":"454","volume":"267","author":"S Sherlock","year":"1954","unstructured":"Sherlock S, Summerskill WH, White LP, Phear EA. Portal-systemic encephalopathy; neurological complications of liver disease. Lancet. 1954;267(6836):454\u20137.","journal-title":"Lancet"},{"key":"1415_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.21001","volume":"43","author":"S Keiding","year":"2006","unstructured":"Keiding S, S\u00f8rensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of 13\u00a0N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology. 2006;43:42\u201350.","journal-title":"Hepatology"},{"key":"1415_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2003.10.016","volume":"40","author":"DL Shawcross","year":"2004","unstructured":"Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol. 2004;40:247\u201354.","journal-title":"J Hepatol"},{"key":"1415_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jhep.2010.07.045","volume":"54","author":"DL Shawcross","year":"2011","unstructured":"Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic inflammation, not ammonia, are associated with grade 3\/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54:640\u20139.","journal-title":"J Hepatol"},{"key":"1415_CR26","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/ajg.2011.123","volume":"106","author":"C Montoliu","year":"2011","unstructured":"Montoliu C, Cauli O, Urios A, ElMlili N, Serra MA, Giner-Duran R, et al. 3-Nitro-Tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol. 2011;106:1629\u201337.","journal-title":"Am J Gastroenterol"},{"key":"1415_CR27","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/liv.12414","volume":"34","author":"CR Bosoi","year":"2014","unstructured":"Bosoi CR, Tremblay M, Rose CF. Induction of systemic oxidative stress leads to brain oedema in portacaval shunted rats. Liver Int. 2014;34:1322\u20139.","journal-title":"Liver Int"},{"key":"1415_CR28","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1665-2681(19)31420-6","volume":"11","author":"V Tripodi","year":"2012","unstructured":"Tripodi V, Contin M, Fern\u00e1ndez MA, Lemberg A. Bile acids content in brain of common duct ligated rats. Ann Hepatol. 2012;11:930\u20134.","journal-title":"Ann Hepatol"},{"key":"1415_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fncel.2017.00191","volume":"11","author":"M McMillin","year":"2017","unstructured":"McMillin M, Frampton G, Grant S, Khan S, Diocares J, Petrescu A, et al. Bile acid-mediated Sphingosine-1-Phosphate receptor 2 signalling promotes neuroinflammation during hepatic encephalopathy in mice. Front Cell Neurosci. 2017;11:191.","journal-title":"Front Cell Neurosci"},{"key":"1415_CR30","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0016-5085(99)70457-9","volume":"117","author":"C Rose","year":"1999","unstructured":"Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, et al. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology. 1999;117:640\u20134.","journal-title":"Gastroenterology"},{"key":"1415_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3174\/ajnr.A1139","volume":"29","author":"A Rovira","year":"2008","unstructured":"Rovira A, Alonso J, C\u00f3rdoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol. 2008;29:1612\u201321.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1415_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2018.08.021","volume":"70","author":"A Hadjihambi","year":"2019","unstructured":"Hadjihambi A, Harrison IF, Costas-Rodr\u00edguez M, Vanhaecke F, Arias N, Gallego-Dur\u00e1n R, et al. Impaired brain glymphatic flow in experimental hepatic encephalopathy. J Hepatol. 2019;70:40\u20139.","journal-title":"J Hepatol"},{"key":"1415_CR33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jsbmb.2015.11.006","volume":"160","author":"RF Butterworth","year":"2016","unstructured":"Butterworth RF. Neurosteroids in hepatic encephalopathy: novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol. 2016;160:94\u20137.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1415_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4161\/gmic.2.2.15416","volume":"2","author":"GM Nava","year":"2011","unstructured":"Nava GM, Stappenbeck TS. Diversity of the autochthonous colonic microbiota. Gut Microbes. 2011;2:99\u2013104.","journal-title":"Gut Microbes"},{"key":"1415_CR35","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","volume":"138","author":"JS Bajaj","year":"2010","unstructured":"Bajaj JS, Schubert CM, Heuman DM, Wade JB, Gibson DP, Topaz A, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138:2332\u201340.","journal-title":"Gastroenterology"},{"key":"1415_CR36","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cgh.2010.10.002","volume":"9","author":"O Riggio","year":"2011","unstructured":"Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2011;9:181\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1415_CR37","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1038\/ctg.2015.38","volume":"6","author":"R Rai","year":"2015","unstructured":"Rai R, Ahuja CK, Agrawal S, Kalra N, Duseja A, Khandelwal N, et al. Reversal of low-grade cerebral edema after lactulose\/rifaximin therapy in patients with cirrhosis and minimal hepatic encephalopathy. Clin Trans Gastroenterol. 2015;6:e111.","journal-title":"Clin Trans Gastroenterol"},{"issue":"3","key":"1415_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3174\/ajnr.A4146","volume":"36","author":"HJ Chen","year":"2015","unstructured":"Chen HJ, Chen R, Yang M, Teng GJ, Herskovits EH. Identification of minimal hepatic encephalopathy in patients with cirrhosis based on white matter imaging and bayesian data mining. AJNR Am J Neuroradiol. 2015;36(3):481\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1415_CR39","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/hep.510290309","volume":"29","author":"JO Clemmesen","year":"1999","unstructured":"Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation, in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology. 1999;29:648\u201353.","journal-title":"Hepatology"},{"key":"1415_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/gut.2004.061754","volume":"55","author":"V Bhatia","year":"2006","unstructured":"Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut. 2006;55:98\u2013104.","journal-title":"Gut"},{"key":"1415_CR41","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/hep.21838","volume":"46","author":"W Bernal","year":"2007","unstructured":"Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46:1844\u201352.","journal-title":"Hepatology"},{"key":"1415_CR42","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/lt.24443","volume":"22","author":"R Sawhney","year":"2016","unstructured":"Sawhney R, Holland-Fischer P, Rosselli M, Mookerjee RP, Agarwal B, Jalan R. Role of ammonia, inflammation, and cerebral oxygenation in brain dysfunction of acute-on-chronic liver failure patients. Liver Transpl. 2016;22:732\u201342.","journal-title":"Liver Transpl"},{"key":"1415_CR43","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00134-013-2926-8","volume":"39","author":"A Drolz","year":"2013","unstructured":"Drolz A, J\u00e4ger B, Wewalka M, Saxa R, Horvatits T, Roedl K, et al. Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med. 2013;39:1227\u201337.","journal-title":"Intensive Care Med"},{"key":"1415_CR44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0002-9343(02)01477-8","volume":"114","author":"JP Ong","year":"2003","unstructured":"Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Lente FV, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med. 2003;114:188\u201393.","journal-title":"Am J Med"},{"key":"1415_CR45","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.cgh.2012.04.011","volume":"10","author":"R Kumar","year":"2012","unstructured":"Kumar R, Shalimar, Sharma H, Prakash S, Panda SK, Khanal S, et al. Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure. Clin Gastroenterol Hepatol. 2012;10:925\u201331.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1415_CR46","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0168-8278(02)00436-1","volume":"38","author":"F Nicolao","year":"2003","unstructured":"Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol. 2003;38:441\u20136.","journal-title":"J Hepatol"},{"key":"1415_CR47","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MCG.0000000000000443","volume":"50","author":"VR Patwardhan","year":"2016","unstructured":"Patwardhan VR, Jiang ZG, Risech-Neiman Y, Piatkowski G, Afdhal NH, Mukamal K, et al. Serum ammonia in associated with transplant-free survival in hospitalized patients with acutely decompensated cirrhosis. J Clin Gastroenterol. 2016;50:345\u201350.","journal-title":"J Clin Gastroenterol"},{"key":"1415_CR48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/hep.30534","volume":"70","author":"MF Shalimar, Sheikh","year":"2019","unstructured":"Shalimar, Sheikh MF, Mookerjee RP, Agarwal B, Acharya SK, Jalan R. Prognostic role of ammonia in patients with cirrhosis. Hepatology. 2019;70:982\u201394.","journal-title":"Hepatology"},{"key":"1415_CR49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/hep.26611","volume":"59","author":"DC Rockey","year":"2014","unstructured":"Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Alexeeva O, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073\u201383.","journal-title":"Hepatology"},{"key":"1415_CR50","first-page":"CD012334","volume":"6","author":"HD Zacharias","year":"2019","unstructured":"Zacharias HD, Zacharias AP, Gluud LL, Morgan MY. Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Cochrane Database Syst Rev. 2019;6:CD012334.","journal-title":"Cochrane Database Syst Rev"},{"key":"1415_CR51","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/liv.14297","volume":"40","author":"J Ampuero","year":"2019","unstructured":"Ampuero J, Gil A, Viloria MDM, Rico MC, Mill\u00e1n R, Camacho I, et al. Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy. Liver Int. 2019;40:921\u201330.","journal-title":"Liver Int"},{"key":"1415_CR52","first-page":"CD003044","volume":"4","author":"LL Gluud","year":"2016","unstructured":"Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044.","journal-title":"Cochrane Database Syst Rev"},{"key":"1415_CR53","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1002\/hep.21930","volume":"46","author":"TI Hassanein","year":"2007","unstructured":"Hassanein TI, Tofteng F, Brown RS, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin Dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46:1853\u201362.","journal-title":"Hepatology"},{"key":"1415_CR54","doi-asserted-by":"crossref","unstructured":"Elsaid MI. RustgiVK.Epidemiology of hepatic encephalopathy.Clin LiverDis,2020;24,:157\u2013174.","DOI":"10.1016\/j.cld.2020.01.001"},{"key":"1415_CR55","first-page":"221","volume":"26","author":"M Uribe","year":"1995","unstructured":"Uribe M, Orozco H, Mor\u00e1n S, Guevara L, Poo JL, Vargas-Vorackova F. Portal-systemic encephalopathy and Gastrointestinal bleeding after cardioselective beta-blocker (metoprolol) administration to patients with portal hypertension. Arch Med Res. 1995;26:221\u20136.","journal-title":"Arch Med Res"},{"key":"1415_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study of the liver. Hepatology. 2014;60:715\u201335.","journal-title":"Hepatology"},{"key":"1415_CR57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12072-017-9812-3","volume":"12","author":"A Hadjihambi","year":"2018","unstructured":"Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy: a critical current review. Hepatol Int. 2018;12:135\u201347.","journal-title":"Hepatol Int"},{"key":"1415_CR58","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1056\/NEJMra1600561","volume":"375","author":"EF Wijdicks","year":"2016","unstructured":"Wijdicks EF. Hepatic encephalopathy. N Engl J Med. 2016;375:1660\u201370.","journal-title":"N Engl J Med"},{"key":"1415_CR59","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrgastro.2010.116","volume":"7","author":"R Prakash","year":"2010","unstructured":"Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515\u201325.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1415_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cld.2012.03.009","volume":"16","author":"V Khungar","year":"2012","unstructured":"Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis. 2012;16:301\u201320.","journal-title":"Clin Liver Dis"},{"key":"1415_CR61","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","volume":"72","author":"HO Conn","year":"1977","unstructured":"Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double-blind controlled trial. Gastroenterology. 1977;72:573\u201383.","journal-title":"Gastroenterology"},{"key":"1415_CR62","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jhep.2021.09.010","volume":"76","author":"VC Patel","year":"2022","unstructured":"Patel VC, Lee S, McPhail MJW, et al. Rifaximin-\u03b1 reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2022;76:332\u201342.","journal-title":"J Hepatol"},{"key":"1415_CR63","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071\u201381.","journal-title":"N Engl J Med"},{"key":"1415_CR64","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1365-2036.2011.04808.x","volume":"34","author":"A Sanyal","year":"2011","unstructured":"Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34:853\u201361.","journal-title":"Aliment Pharmacol Ther"},{"key":"1415_CR65","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1345\/aph.1R146","volume":"46","author":"RA Mohammad","year":"2012","unstructured":"Mohammad RA, Regal RE, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother. 2012;46:1559\u201363.","journal-title":"Ann Pharmacother"},{"key":"1415_CR66","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/1060028016645826","volume":"50","author":"T Jawaro","year":"2016","unstructured":"Jawaro T, Yang A, Dixit D, Bridgeman MB. Management of hepatic encephalopathy: A primer. Ann Pharmacother. 2016;50:569\u201377.","journal-title":"Ann Pharmacother"},{"key":"1415_CR67","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-1-4615-1989-8_13","volume":"368","author":"RA Hawkins","year":"1994","unstructured":"Hawkins RA, Jessy J, Mans AM, Chedid A, DeJoseph MR. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol. 1994;368:125\u201334.","journal-title":"Adv Exp Med Biol"},{"key":"1415_CR68","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/BF01072921","volume":"23","author":"CE Atterbury","year":"1978","unstructured":"Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portalsystemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23:398\u2013406.","journal-title":"Am J Dig Dis"},{"key":"1415_CR69","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","volume":"72","author":"HO Conn","year":"1977","unstructured":"Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double-blind controlled trial. Gastroenterology. 1977;72:573\u201383.","journal-title":"Gastroenterology"},{"key":"1415_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/gut.23.1.1","volume":"23","author":"MH Morgan","year":"1982","unstructured":"Morgan MH, Read AE, Speller DC. Treatment of hepatic encephalopathy with metronidazole. Gut. 1982;23:1\u20137.","journal-title":"Gut"},{"key":"1415_CR71","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/hep.510250609","volume":"25","author":"G Kircheis","year":"1997","unstructured":"Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997;25:1351\u201360.","journal-title":"Hepatology"},{"key":"1415_CR72","doi-asserted-by":"crossref","unstructured":"Marchesini G, Fabbri A, Bianchi G, et al. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology. 1996 May;23(5):1084\u201392.","DOI":"10.1002\/hep.510230523"},{"key":"1415_CR73","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/gut.23.5.362","volume":"23","author":"MY Morgan","year":"1982","unstructured":"Morgan MY, Marshall AW, Milsom JP, Sherlock S. Plasma amino-acid patterns in liver disease. Gut. 1982;23:362\u201370.","journal-title":"Gut"},{"key":"1415_CR74","first-page":"CD001939","volume":"5","author":"LL Gluud","year":"2017","unstructured":"Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;5:CD001939.","journal-title":"Cochrane Database Syst Rev"},{"key":"1415_CR75","first-page":"346","volume":"26","author":"A Watanabe","year":"1979","unstructured":"Watanabe A, Takesue A, Higashi T, Nagashima N. Serum amino acids in hepatic encephalopathy\u2013effects of branched chain amino acid infusion on serum aminogram. Acta Hepatogastroenterol (Stuttg). 1979;26:346\u201357.","journal-title":"Acta Hepatogastroenterol (Stuttg)"},{"key":"1415_CR76","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/MEG.0000000000002595","volume":"35","author":"WD Swansson","year":"2023","unstructured":"Swansson WD, Anderson BM, Yeoh SW, Lewis DJ. Management of minimal and overt hepatic encephalopathy with branched-chain amino acids: a review of the evidence. Eur J Gastroenterol Hepatol. 2023;35:812\u201321.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1415_CR77","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1097\/00003246-200009000-00032","volume":"28","author":"AI Qureshi","year":"2000","unstructured":"Qureshi AI, Suarez JI. Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. Crit Care Med. 2000;28:3301\u201313.","journal-title":"Crit Care Med"},{"key":"1415_CR78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11940-010-0062-0","volume":"12","author":"AA Rabinstein","year":"2010","unstructured":"Rabinstein AA. Treatment of brain edema in acute liver failure. Curr Treat Options Neurol. 2010;12:129\u201341.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"1415_CR79","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-8278(86)80007-1","volume":"2","author":"RJ Ede","year":"1986","unstructured":"Ede RJ, Gimson AES, Bihari D, Williams R. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol. 1986;2(1):43\u201351.","journal-title":"J Hepatol"},{"issue":"3","key":"1415_CR80","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00003246-199003000-00008","volume":"18","author":"A Davenport","year":"1990","unstructured":"Davenport A, Will EJ, Davison AM. Effect of posture on intracranial pressure and cerebral perfusion pressure in patients with fulminant hepatic and renal failure after acetaminophen self-poisoning. Crit Care Med. 1990;18(3):286\u20139.","journal-title":"Crit Care Med"},{"issue":"2","key":"1415_CR81","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8278(88)80006-0","volume":"28","author":"G Strauss","year":"1998","unstructured":"Strauss G, Hansen BA, Knudsen GM, Larsen FS. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol. 1998;28(2):199\u2013203.","journal-title":"J Hepatol"},{"key":"1415_CR82","doi-asserted-by":"crossref","unstructured":"Wijdicks EFM, Nyberg SL. Propofol to control intracranial pressure in fulminant hepatic failure. Transplantation Proceedings. 2002;34(4):1220\u20131222.","DOI":"10.1016\/S0041-1345(02)02804-X"},{"issue":"4","key":"1415_CR83","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-2007-1007251","volume":"16","author":"A Ellis","year":"1996","unstructured":"Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis. 1996;16(4):379\u201387.","journal-title":"Semin Liver Dis"},{"issue":"8909","key":"1415_CR84","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(94)92471-6","volume":"343","author":"MH Davies","year":"1994","unstructured":"Davies MH, Mutimer D, Lowes J, Elias E, Neuberger J. Recovery despite impaired cerebral perfusion in fulminant hepatic failure. Lancet. 1994;343(8909):1329\u201330.","journal-title":"Lancet"},{"issue":"9","key":"1415_CR85","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1097\/00042737-199909000-00004","volume":"11","author":"K Moore","year":"1999","unstructured":"Moore K. Renal failure in acute liver failure. Eur J Gastroenterol Hepatol. 1999;11(9):967\u201375.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"1415_CR86","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-2003-42645","volume":"23","author":"R Jalan","year":"2003","unstructured":"Jalan R. Intracranial hypertension in acute liver failure: pathophysiological basis of rational management. Semin Liver Dis. 2003;23(3):271\u201382.","journal-title":"Semin Liver Dis"},{"issue":"4","key":"1415_CR87","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0168-8278(98)80154-2","volume":"29","author":"J Cordoba","year":"1998","unstructured":"Cordoba J, Gottstein J, Blei AT. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis. J Hepatol. 1998;29(4):589\u201394.","journal-title":"J Hepatol"},{"issue":"2","key":"1415_CR88","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/hep.20056","volume":"39","author":"N Murphy","year":"2004","unstructured":"Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004;39(2):464\u201370.","journal-title":"Hepatology"},{"issue":"4","key":"1415_CR89","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1055\/s-2007-1007252","volume":"16","author":"N Rolando","year":"1996","unstructured":"Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996;16(4):389\u2013402.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"1415_CR90","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/lt.500020103","volume":"2","author":"N Rolando","year":"1996","unstructured":"Rolando N, Wade JJ, Stangou A, et al. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. Liver Transplantation Surg. 1996;2(1):8\u201313.","journal-title":"Liver Transplantation Surg"},{"issue":"7","key":"1415_CR91","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/gut.23.7.625","volume":"23","author":"J Canalese","year":"1982","unstructured":"Canalese J, Gimson AES, Davis C. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut. 1982;23(7):625\u20139.","journal-title":"Gut"},{"key":"1415_CR92","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/gut.21.10.866","volume":"21","author":"MA Hanid","year":"1980","unstructured":"Hanid MA, Davies M, Mellon PJ, et al. Clinical monitoring of intracranial pressure in fulminant hepatic failure. Gut. 1980;21:866\u20139.","journal-title":"Gut"},{"issue":"3","key":"1415_CR93","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1053\/jhep.2000.9775","volume":"32","author":"AJ Ellis","year":"2000","unstructured":"Ellis AJ, Wendon JA, Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology. 2000;32(3):536\u201341.","journal-title":"Hepatology"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01415-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11910-025-01415-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-025-01415-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:51:29Z","timestamp":1743501089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11910-025-01415-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1007\/s11910-025-01415-9","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"7 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"28"}}